Moderna (MRNA) · Deep analysis

Report previewMRNA.USReport date Last updated
← Back to reports
Report contents

At a glance

  • Business model: Moderna sells vaccine doses, mainly COVID-19, to national health authorities and insurers, with pharmacies serving retail demand. The payer is a procurement office answering to a budget cycle rather than a patient, so price per dose and volume trade off directly. Nearly every product meant to diversify revenue still depends on a regulatory recommendation or national access decision.
  • Financial quality: Operating cash flow has been negative since FY2023, with free cash flow of -USD 2.06bn in FY2025 and about -USD 1.25bn in the first half of FY2026. Cash of USD 1.72bn at June 30, 2026 sits against USD 2.53bn of current liabilities, and the supplied data omits current assets, inventory, and whether that cash line includes marketable securities. No long-term debt is disclosed, so the burn, not leverage, binds.
01

Business model

Moderna sells vaccines, and it sells the promise of a platform. Revenue today comes from respiratory vaccine doses — mainly its COVID-19 product — bought in bulk by national health authorities, with pharmacies and distributors serving retail demand. Governments and insurers pay; patients rarely do. Pricing is per dose under procurement contracts, and revenue is recognized on shipment, so a single national tender can move a whole quarter. That makes Moderna a commercial-stage vaccine manufacturer with a research pipeline attached. The stage is turnaround: its 10-Q for the quarter ended June 30, 2026 frames the year around a return to sales growth, a prioritized R&D portfolio, and cost efficiency.

The payer is a procurement office, not a patient

Two forces drive the revenue line, and they have different causes. The direct cause is demand normalization: emergency pandemic purchasing has given way to seasonal, age-targeted immunization, so both the number of doses and the urgency behind them are smaller. The structural cause is buyer concentration. In most countries a health ministry is effectively the single purchaser for its whole population, can choose among a few approved suppliers, and answers to a budget cycle rather than a patient's willingness to pay. The clearing price is set by that budget, not by Moderna's cost of goods.

That creates a real tradeoff. Moderna can defend price per dose and accept lower volume, or discount to hold immunization-program slots and shelf space. The two move together: a discount that wins a tender raises revenue while lowering the contribution from every dose shipped, which is why a headline return to growth would not by itself settle the business-quality question.

What would overturn the pessimistic read is disclosed multi-year supply commitments at stable pricing, or reimbursement decisions in large markets that add Moderna products without rebate pressure. Public procurement records eventually show the outcome, but they are uneven across countries and reported with a lag.

Growth depends on products that are not approved yet

The revenue mix is the crux. The 10-Q's forward-looking topics list a return to sales growth in 2026, the size and durability of the respiratory vaccine market, mCOMBRIAX availability across the EU subject to national regulatory and access procedures, potential near-term approval of mFLUSIVA, and Phase 3 adjuvant melanoma data for mRNA-4157 in 2026. Read that list as a portfolio: today's revenue is concentrated in COVID-19, and nearly everything intended to diversify it still depends on a regulatory or access decision.

The structural point is where value is created in vaccines. It is not at the prescription. It is at the advisory recommendation and the national access procedure — the steps that determine whether a product gets paid for at all. Clinical data is necessary and not sufficient. A product can win approval and still earn little if a national body declines to recommend it or sets a low reimbursed price. That is why mCOMBRIAX access procedures matter as much as the approval itself, and why the mRNA-4157 readout expected in 2026 is the clearest single swing factor in the story.

One caveat on evidence: the supplied filing material is the 10-Q cover page and the forward-looking statement list. The product, geographic, and segment revenue tables are not in it, so the mix described here reflects the company's stated priorities rather than a verified percentage breakdown.

Fixed plants against seasonal, unpredictable volume

Vaccine manufacturing is built ahead of a short season, and mRNA production is capital-intensive. The direct cause of cost pressure is unsold doses and idle capacity in the months when lines aren't running. The structural cause is that the asset base was scaled for pandemic volumes while demand has reverted to seasonal, age-targeted use. The 10-Q names cost of sales as a percentage of net product sales as an expected swing factor, which is management conceding that the volume-versus-capital tradeoff is live: run plants fuller and risk write-offs on unsold inventory, or run leaner and risk missing a season's demand.

What the pipeline funding question comes down to

Cash from the commercial base funds the pipeline, and the pipeline is what investors are paying for. The filing lists financing and funding options as a forward-looking consideration, which I read as leaving the funding question open rather than settled; that is inference, not disclosure. The consequence is straightforward. If mRNA-4157 data support a filing, Moderna holds a second franchise with a demand cycle that does not track respiratory tenders. If not, it is a seasonal vaccine maker competing on price against larger manufacturers with broader product lines, and the fixed-cost base becomes the dominant variable in earnings and cash.

Questions worth following

  • Can Moderna return to product sales growth in 2026 without conceding price to government buyers?

    Vaccine revenue depends on how many doses national health programs buy and at what price. If growth requires deeper discounts, the COVID base can stabilize on paper while margins and cash generation stay below the levels the pipeline needs to fund itself.

  • Will mRNA-4157's Phase 3 melanoma results establish a second commercial franchise beyond respiratory vaccines?

    Oncology is the clearest path to revenue that does not depend on seasonal respiratory tenders. Positive adjuvant melanoma data could support a filing and a durable treatment franchise; disappointing data would leave Moderna competing for the same procurement budgets with flu and combination products.

  • Can Moderna match its manufacturing footprint to seasonal vaccine demand without heavy idle capacity?

    Vaccine demand is seasonal and concentrated in a few months, while mRNA plants are fixed-cost assets built for pandemic volumes. The utilization outcome helps decide whether cost of sales stays elevated as a share of net product sales, and therefore how much cash is left for the pipeline.

02

Financial quality

II. Financial Quality: A COVID Windfall Funding a Much Smaller Company

Moderna does not have a leverage problem. It has a funding problem. Long-term debt is not disclosed in any period supplied, short-term debt is $0.05bn, and interest expense was $0.02bn in the June 2026 quarter. Liabilities equaled 38.3% of assets at June 30, 2026, up from 22.9% two years earlier — but that rise comes from shrinking equity, not from borrowing. Three consecutive years of negative operating cash flow have pulled cash from $6.85bn at the end of FY2021 to $1.72bn. In FY2025, the operating loss ($3.07bn) was larger than the entire year's revenue ($1.94bn).

The five-year record: a windfall, then a much smaller business
Metric (USD bn unless noted)FY2021FY2022FY2023FY2024FY2025Q2 FY2026 (interim)Assessment
Revenue17.7418.886.853.201.940.14Very weak — FY2025 is 10% of the FY2022 peak
Gross profit15.1213.462.161.741.080.05Weak
Gross margin85.2%71.3%31.5%54.4%55.7%35.7%Adequate but fragile — ~1% at peak volume in Q3 FY2025
Operating income13.309.42-4.24-3.95-3.07-0.82Very weak
Net income12.208.36-4.71-3.56-2.82-0.78Very weak
Operating cash flow13.624.98-3.12-3.00-1.87-0.53Very weak — negative three years running
Capex (derived)0.280.400.711.050.190.03Weak — the buildout has stopped
Free cash flow13.344.58-3.83-4.05-2.06-0.56Very weak
Total assets24.6725.8618.4314.1412.3410.96Weak
Total liabilities10.526.734.573.243.694.20Adequate — almost no debt
Total equity14.1419.1213.8510.908.656.76Weak
Liabilities/assets42.6%26.0%24.8%22.9%29.9%38.3%Adequate — rising because equity is shrinking
Cash6.853.202.911.932.591.72Weak — 75% below FY2021
Cash / current liabilities0.750.650.970.871.300.68Weak — may exclude marketable securities

Flows in the Q2 FY2026 column are single-quarter figures; balances are as of June 30, 2026. Capex is derived as operating cash flow minus free cash flow. Current assets and net PP&E are not disclosed in any supplied period, so a current ratio cannot be computed.

The contraction is structural, not a down cycle. Cash conversion is the real story: operating cash flow has been negative since FY2023, so the usual cash-to-earnings comparison is meaningless here. The binding arithmetic is burn against the cash balance — -$2.06bn of free cash flow in FY2025, then -$1.25bn in the first half of FY2026, against $1.72bn of cash. One caveat: the supplied cash line may exclude marketable securities, which would make total liquidity larger than $1.72bn.

Six quarters: the fourth quarter's cash is a collection, not a recovery

Only six quarters are available, beginning with FY2025 Q1.

Metric (USD bn)FY25 Q1FY25 Q2FY25 Q3FY25 Q4FY26 Q1FY26 Q2AssessmentTrend
Revenue0.110.141.020.680.390.14WeakQ3 spike not repeated
Gross profit0.020.020.010.23-0.570.05Very weak~zero at peak volume; negative in FY26 Q1
Net income-0.97-0.82-0.20-0.83-1.34-0.78Very weakNo quarter near breakeven
Operating cash flow-1.04-0.92-0.850.95-0.63-0.53WeakPositive only on Q3 collections
Free cash flow-1.16-0.92-0.880.91-0.69-0.56Very weakNegative in five of six quarters
Total assets12.7012.0112.1312.3411.4910.96WeakDown 14% over six quarters
Total liabilities2.642.612.813.694.084.20WatchUp 59% over six quarters
Cash1.621.281.132.591.911.72WeakFY25 Q4 peak not sustained
Current liabilities1.601.571.681.992.402.53WatchRising faster than cash

The FY2025 Q3-to-Q4 swing is the tell. Q3 revenue of $1.02bn produced about $0.01bn of gross profit and $0.85bn of operating cash outflow. Q4 revenue of $0.68bn produced +$0.95bn of operating cash and lifted cash by $1.46bn. Respiratory shots ship before they are paid for, so the fourth quarter harvests the third quarter's sales. Annual figures are the honest ones, and they show a company still consuming cash at roughly $0.6bn a quarter.

Three relationships that decide the next two years

Volume against a fixed manufacturing base. Gross margin of 85.2% in FY2021 and 55.7% in FY2025 looks tolerable in isolation, but the quarterly detail says otherwise: the largest revenue quarter of FY2025 earned almost no gross profit, and FY2026 Q1 gross profit was negative (−$0.57bn on $0.39bn of revenue). Capacity, supply agreements, and staffing were built for a COVID-scale business. When volume collapsed, unabsorbed fixed costs — and probably inventory charges — landed on a small revenue base. Operating expense cuts cannot fix this, because FY2025's operating loss exceeded its revenue. This is structural; seasonality affects only the timing.

Losses funded by equity, not debt. Cumulative net losses from FY2023 through FY2025 were $11.1bn, and equity fell from $19.12bn to $8.65bn. In FY2025 alone, a $2.82bn loss produced only a $2.25bn decline in equity, implying roughly $0.57bn of equity credits — consistent with stock-based compensation and employee share issuance. That matters for cash-flow quality: stock compensation is added back in operating cash flow, so the reported burn leaves out a real cost borne by holders. The 10-Q cover reports 399.2 million shares outstanding as of July 24, 2026. The direction of that count, not its level, is what to watch.

Cash arriving from the balance sheet rather than operations. FY2025 showed a $0.56bn financing inflow concentrated in Q4 and a $1.95bn investing inflow against derived capex of only $0.19bn. The investing figure looks like maturities of a securities portfolio rather than asset sales, and the financing item is not identified in the supplied data. Until the filings explain them, a meaningful share of recent cash came from balance-sheet activity rather than the business.

Three things the filings need to explain
  • Cost of sales composition. Near-zero and then negative gross profit at commercial volumes points to inventory write-downs, idle-capacity charges, or unprofitable supply commitments. Inventory is not disclosed in any supplied period.
  • The definition of liquidity. Cash of $1.72bn against $2.53bn of current liabilities, with current assets undisclosed, cannot be converted into a current ratio from this data. What counts as cash, equivalents, and investments — and their maturity ladder — requires the filing.
  • The FY2025 Q4 financing inflow of $0.56bn. Whether that was a lease, government arrangement, partnership contribution, or borrowing changes how much of the year's cash came from operations.
What would change the judgment

Revenue growth with gross margin holding above the mid-50% range on non-COVID products, a quarterly burn narrowing toward zero, and any non-dilutive funding that extends the runway would each improve the read. Another equity raise, a widening burn, or recurring write-downs would confirm that the pipeline has been funded by the 2021–2022 windfall — and that the windfall is nearly spent.

Questions worth following

  • Can Moderna fund its pipeline to a first oncology launch without another large equity raise?

    Roughly $1.7bn of cash and about $1.25bn of first-half free cash outflow leave little room before outside capital is needed. Whether existing resources stretch to a commercial oncology launch determines dilution for holders, not just near-term liquidity.

  • Can Moderna match its manufacturing footprint to seasonal vaccine demand without heavy idle capacity?

    Vaccine demand is seasonal and concentrated in a few months, while mRNA plants are fixed-cost assets built for pandemic volumes. The utilization outcome helps decide whether cost of sales stays elevated as a share of net product sales, and therefore how much cash is left for the pipeline.

  • Will Moderna's cost cuts reduce its cash burn without leaning on further shareholder dilution?

    Equity, not debt, has absorbed the losses, and stock compensation is added back in operating cash flow. Shrinking the cost base through employees instead of share issuance would make the burn reduction durable and slow the transfer of value away from existing holders.

Generated by DeepVal AI. Data and models may contain errors or be outdated. For research only; not personalized investment advice.

Go beyond the preview

Continue reading the full report

  1. Key risksWhat could break the investment case
  2. Valuation and margin of safetyWhat the current price assumes, and how much room for error it leaves
  3. SummaryOur overall judgement and what to watch next

Free to sign up · 20 research points · unlocking this report uses 10

20 points cover 2 full reports. No card needed.

Research reflects its generation date. Preview the first two modules.

More on Moderna Inc